Literature DB >> 12591736

Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Akseli Hemminki1, Anna Kanerva, Bin Liu, Minghui Wang, Ronald D Alvarez, Gene P Siegal, David T Curiel.   

Abstract

An important determinant of gene transfer efficacy with adenoviral vectors is expression of the primary receptor, the coxsackie-adenovirus receptor. Unfortunately, expression may often be low in advanced clinical cancers, including ovarian, colorectal, lung, prostate, and breast cancer. In this study we investigated the feasibility of increasing transgene expression by incubating ovarian cancer cells with various agents and then performing transgene expression analysis. Fluorescence-activated cell sorting and quantitative reverse transcription-PCR were subsequently performed for correlation with receptor and mRNA up-regulation. Furthermore, the results were confirmed in purified clinical ovarian cancer specimens. Possible clinical application was tested using i.p. administration in an orthotopic ovarian cancer animal model. This approach could be useful for increasing adenoviral transgene expression in the context of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591736

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells.

Authors:  Theresa Vincent; Ralf F Pettersson; Ronald G Crystal; Philip L Leopold
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

3.  Structural variations in species B adenovirus fibers impact CD46 association.

Authors:  Lars Pache; Sangita Venkataraman; Vijay S Reddy; Glen R Nemerow
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

4.  5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.

Authors:  Xiao W Huang; Zhao Y Tang; Theodore S Lawrence; Ming Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2004-11-09       Impact factor: 4.553

5.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

Review 6.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

7.  Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor.

Authors:  E M Lee; S H Hong; Y J Lee; Y H Kang; K C Choi; S H Choi; I H Kim; S J Lim
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-16       Impact factor: 4.553

8.  A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells.

Authors:  Yang Zhan; Bin Yu; Zhen Wang; Yu Zhang; Hai-Hong Zhang; Hao Wu; Xiao Feng; Ran-Shen Geng; Wei Kong; Xiang-Hui Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Authors:  Misato Takagi-Kimura; Tomoki Yamano; Atsuko Tamamoto; Nobutaka Okamura; Haruki Okamura; Tomoko Hashimoto-Tamaoki; Masatoshi Tagawa; Noriyuki Kasahara; Shuji Kubo
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

10.  Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix.

Authors:  Dror Kolodkin-Gal; Gideon Zamir; Yair Edden; Eli Pikarsky; Alon Pikarsky; Hillel Haim; Yosef S Haviv; Amos Panet
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.